guaifenesin has been researched along with Cardiovascular Diseases in 5 studies
Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The term phenotype in the field of COPD is defined as "a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes"." | 2.48 | Clinical phenotypes of COPD: identification, definition and implications for guidelines. ( Calle, M; Miravitlles, M; Soler-Cataluña, JJ, 2012) |
| "The development of COPD is associated with chronic pulmonary inflammation." | 2.46 | [COPD and inflammation: statement from a French expert group: inflammation and remodelling mechanisms]. ( Aguilaniu, B; Aubier, M; Berger, P; Brillet, PY; Burgel, PR; Chambellan, A; Chanez, P; Chaouat, A; Devillier, P; Escamilla, R; Louis, R; Mal, H; Marthan, R; Muir, JF; Pérez, T; Roche, N; Similowski, T; Wallaert, B, 2010) |
| "Acute respiratory infections (ARI) are extremely common at all ages, mostly mild self-limiting illnesses at a young age, but severe often fatal illnesses in elderly people already affected by a chronic disease such as COPD." | 2.42 | Determinants of prognosis of COPD in the elderly: mucus hypersecretion, infections, cardiovascular comorbidity. ( Lange, P; Miller, DL; Pistelli, R, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, HS | 1 |
| Sim, HJ | 1 |
| Cho, H | 1 |
| Bang, WY | 1 |
| Kim, HE | 1 |
| Kwon, TK | 1 |
| Kwon, T | 1 |
| Park, TJ | 1 |
| Aubier, M | 1 |
| Marthan, R | 1 |
| Berger, P | 1 |
| Chambellan, A | 1 |
| Chanez, P | 1 |
| Aguilaniu, B | 1 |
| Brillet, PY | 1 |
| Burgel, PR | 1 |
| Chaouat, A | 1 |
| Devillier, P | 1 |
| Escamilla, R | 1 |
| Louis, R | 1 |
| Mal, H | 1 |
| Muir, JF | 1 |
| Pérez, T | 1 |
| Similowski, T | 1 |
| Wallaert, B | 1 |
| Roche, N | 1 |
| Miravitlles, M | 1 |
| Calle, M | 1 |
| Soler-Cataluña, JJ | 1 |
| Pistelli, R | 1 |
| Lange, P | 1 |
| Miller, DL | 1 |
| Ebi-Kryston, KL | 1 |
| Hawthorne, VM | 1 |
| Rose, G | 1 |
| Shipley, MJ | 1 |
| Gillis, CR | 1 |
| Hole, DJ | 1 |
| Carmen, W | 1 |
| Eshleman, S | 1 |
| Higgins, MW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Fluticasone Furoate/Vilanterol vs. Umeclidinium/Vilanterol in Patients With COPD-asthma Phenotype vs. Emphysema Phenotype. A Controled Clinical Trial.[NCT05342558] | Phase 4 | 133 participants (Actual) | Interventional | 2017-09-19 | Completed | ||
| Raman Analysis of Saliva From COPD Patients as New Biomarker: AI-based Point-of-care for the Disease Monitoring and Management[NCT04628962] | 250 participants (Anticipated) | Observational | 2022-02-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for guaifenesin and Cardiovascular Diseases
| Article | Year |
|---|---|
[COPD and inflammation: statement from a French expert group: inflammation and remodelling mechanisms].
Topics: Airway Remodeling; Anemia; Antigens; Antioxidants; Bronchitis; Cardiovascular Diseases; Comorbidity; | 2010 |
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato | 2012 |
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato | 2012 |
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato | 2012 |
Clinical phenotypes of COPD: identification, definition and implications for guidelines.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asthma; Bronchiectasis; Bronchitis; Bronchodilato | 2012 |
Determinants of prognosis of COPD in the elderly: mucus hypersecretion, infections, cardiovascular comorbidity.
Topics: Aged; Air Pollution; Cardiovascular Diseases; Comorbidity; Humans; Mucus; Prognosis; Pulmonary Disea | 2003 |
2 other studies available for guaifenesin and Cardiovascular Diseases
| Article | Year |
|---|---|
Alpha-tocopherol exerts protective function against the mucotoxicity of particulate matter in amphibian and human goblet cells.
Topics: Air Pollutants; Air Pollution; alpha-Tocopherol; Animals; Anura; Cardiovascular Diseases; Cell Line, | 2020 |
Breathlessness, chronic bronchitis and reduced pulmonary function as predictors of cardiovascular disease mortality among men in England, Scotland and the United States.
Topics: Adult; Bronchitis; Cardiovascular Diseases; Chronic Disease; England; Follow-Up Studies; Forced Expi | 1989 |